このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

WuXi Biologics (Cayman) バランスシートの健全性

財務の健全性基準チェック /56

WuXi Biologics (Cayman)の総株主資本はCN¥44.0B 、総負債はCN¥2.1Bで、負債比率は4.9%となります。総資産と総負債はそれぞれCN¥56.6BとCN¥12.6Bです。 WuXi Biologics (Cayman)の EBIT はCN¥3.9Bで、利息カバレッジ比率-64.8です。現金および短期投資はCN¥11.2Bです。

主要情報

4.9%

負債資本比率

CN¥2.15b

負債

インタレスト・カバレッジ・レシオ	-64.8x
現金	CN¥11.24b
エクイティ	CN¥44.02b
負債合計	CN¥12.56b
総資産	CN¥56.58b

財務の健全性に関する最新情報

更新なし

Recent updates

財務状況分析

短期負債: WXXW.Yの短期資産 ( CN¥21.2B ) が短期負債 ( CN¥7.6B ) を超えています。

長期負債: WXXW.Yの短期資産 ( CN¥21.2B ) が長期負債 ( CN¥4.9B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: WXXW.Y総負債よりも多くの現金を保有しています。

負債の削減: WXXW.Yの負債対資本比率は、過去 5 年間で0%から4.9%に増加しました。

債務返済能力: WXXW.Yの負債は営業キャッシュフローによって十分にカバーされています ( 217.4% )。

インタレストカバレッジ: WXXW.Y支払う利息よりも稼ぐ利息の方が多いので、利息支払いの補償は問題になりません。

WuXi Biologics (Cayman) バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Recent updates

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed into an Asset Purchase Agreement to acquire Drug Substance Facility in Wuppertal from Bayer Aktiengesellschaft (XTRA:BAYN) for € 110 million.

Arcus Biosciences, Inc. Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

WuXi Biologics and AB2 Bio Ltd. Announces Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

WuXi Biologics (Cayman) Inc. has completed a Follow-on Equity Offering in the amount of HKD 6.165 billion.

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

健全な企業の発掘

財務の健全性基準チェック /56